NCCN Guidelines Reflect Recent FDA Approvals for Hematologic Malignancies

Published: Wednesday, Feb 13, 2019
 Meletios A. Dimopoulos, MD
Meletios A. Dimopoulos, MD
New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.

Waldenström Macroglobulinemia

The FDA recently approved ibrutinib (Imbruvica) plus rituximab (Rituxan) for the treatment of Waldenström macroglobulinemia (WM), or lymphoplasmacytic lymphoma, a rare form of B-cell lymphoma that is characterized by bone marrow infiltration by lymphoplasmacytic cells.2 The approval expands the label of ibrutinib in WM from its currently approved use as monotherapy to include the first nonchemotherapy combination in this malignancy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x